Quality of life factors in advanced breast cancer patients (ABCP), treated with metronomic chemotherapy (MCT) with cyclophosphamide (Cy) and celecoxib (Cel). Preliminary results of a Phase I/II trial

PERROUD HA, ROZADOS VR, ALASINO CM, RICO MJ, PEZZOTTO SM, SCHAROVSKY OG.

Rosario,Santa Fe

Congreso; XII Congreso y XXX Reunión Anual de la Sociedad de Biología de Rosario; 2010

Chemotherapeutic agents (CA) used at maximum tolerated dose (MTD) are limited by toxicity, non-specificity and resistance development, with a detriment of quality of life. MCT consists in the chronic administration, at regular intervals, of low doses of CA, without extended rest periods. Our goal was to analyze the quality of life of the patients enrolled in the trial up to now. ABCP received 50mg Cyclophosphamide+400mg Celecoxib/day, p.o. Clinical and biochemical evaluations were performed every 15-30 days. Quality of life or performance status was determined by ECOG scale. Patients included in the trial remained in treatment 4 to 34 weeks, without showing serious toxicity. A decline in platelet count Grade II in 1/7 patients, an increase in CPK levels in 1/7 patients, and the absence of toxicity in 5/7 patients were observed. Quality life evaluation indicated absence of adverse events and the presence of some positive changes, i.e: decrease in the morphine daily dose, improvement in mobilization. A reduction of one point in the ECOG scale in 5/7 patients and no change in the remaining 2 was also observed. We conclude that although in MCT, the cumulative Cy doses per patient in 21 days are similar to MTD schemes: 1) no important toxic effects were detected 2) An improvement in patients quality of life was obtained.